A Phase 1 interventional study of Psilocybin in PTSD, sponsored by University of New Mexico. Recruiting at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by University of New Mexico · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing psilocybin in Stress Disorders, Post-Traumatic — 13 open to participants now, 16 under way, 3 of them phase 3. Psilocybin · Stress Disorders, Post-Traumatic.
Among the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic, this one is the 10th largest by planned enrollment, is one of 7 that started in 2026, is one of 6 in phase 1, reaches primary completion later than 7 of the 15 other live ones, and was the 16th registered.
2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →13 of the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic are open now, in 5 countries. Recruiting first, the newest first:
COMPASS Pathways · Sites in United States, Canada
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18–75
Sunstone Medical · Sites in United States
Ages 18+ · Women only
Khyber Medical University Peshawar · Sites in Pakistan
Ages 18–60
Johns Hopkins University · Sites in United States
Ages 21+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.
This study: 18 Years to 89 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 11 · Phase 3 4
First in 2022; this study’s year is marked. 7 started in 2026.
This study's planned enrollment of 36 is below the median of 69 across 2,203 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 33 across the 20 interventional studies. Of the 3 that completed or were terminated, 2 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 20 have an industry lead sponsor. The 10 most frequent:
University of New Mexico is the lead sponsor of 313 studies on the registry; 27 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 23 (88%) have results posted.
10 studies in Stress Disorders, Post-Traumatic by University of New Mexico: 4 open now, 4 under way, none of them phase 3. Of 4 finished, 2 (50%) have results posted.
Among the 10 studies in Stress Disorders, Post-Traumatic by University of New Mexico, this one is the 5th largest by planned enrollment, is one of 3 that started in 2026, is the only one in phase 1, and was the 9th registered.
University of New Mexico’s Stress Disorders, Post-Traumatic studies by the year they started, since 2011.
5 of the studies testing psilocybin in Stress Disorders, Post-Traumatic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07703722Phase 3Khyber Medical University PeshawarEffect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder | 2027-10-22 |
| NCT07737054Tel-Aviv Sourasky Medical CenterTrauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for PTSD | 2026-12-01 |
| NCT06888128Baylor College of MedicineState-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma | 2026-12-15 |
| NCT07506395University of New MexicoGroup Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder | 2027-05-01 |
| NCT06902974Sunstone MedicalPsilocybin-Assisted Therapy for Sexual Assault-Related PTSD | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic, from their registry updates:
Among University of New Mexico’s 10 in Stress Disorders, Post-Traumatic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a community-informed, pragmatic, open-label, phase 1 clinical trial of group-format psilocybin-assisted therapy (GPAT) for individuals with post-traumatic stress disorder (PTSD). The primary objectives of this phase 1 study are to assess the safety and feasibility of (GPAT) for individuals with (PTSD) and to evaluate preliminary effects on PTSD severity.
This study is a community-informed, pragmatic, open-label, phase 1 clinical trial of group-format psilocybin-assisted therapy (GPAT) for individuals with post-traumatic stress disorder (PTSD). The primary objectives of this phase 1 study are to assess the safety and feasibility of (GPAT) for individuals with (PTSD) and to evaluate preliminary effects on PTSD severity.
These will be assessed by the following outcome measures:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
General:
-T+H years of age and \<89 years of age
Identify as a member of one of the cohorts to be studied:
PTSD severity:
Exclusion Criteria:
Cardiovascular conditions:
Neurological conditions (e.g. epilepsy or other seizure disorder) or neurodegenerative disease (e.g., dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis.), or brain tumor that would impact participation in the trial Serious abnormalities of complete blood count or chemistry
Any of the following psychiatric conditions:
Using daily dose of psilocybin mushrooms at dose \<0.2 mg or LSD at \<20 mcg per day for \<30 days in a year ("microdosing") will not be an exclusion criterion.
However, participants must agree to no further use of psychedelics during this study starting at screening.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Psilocybin
Two group-format dosing sessions, scheduled 4 weeks apart, will be held at the ISUBI Center at UNM or a site outside of UNM with DEA approval for psilocybin storage
Rate of study completion-feasabiity measure
Number of participants that completed the study.
Time frame: 18 weeks after baseline
Clinician-Administered PTSD Scale for DSM-5
The Clinician-Administered PTSD Scale for DSM-5 is a 30-item structured interview that determines a PTSD diagnosis and severity by assessing the frequency and intensity of 20 DSM-5 symptoms. Each symptom is rated on a 0-4 scale (0=absent, 4=extreme), with a total severity score calculated by summing individual item scores. Total Range: 0-80 (sum of 20 items) total scores indicate severity, with higher ratings indicating worse PTSD symptoms.
Time frame: baseline and 18 weeks
Incidence of adverse events (AEs), serious adverse events (SAEs) and AEs of special interest using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
adverse event assessment as safety measure
Time frame: 18 weeks after baseline
Beck Depression Inventory-II
The Beck Depression Inventory-II is a 21-item, 4-point Likert scale (0-3) self-report questionnaire depression assessment with a minimum score of 0 and a maximum score of 63; higher scores indicate greater depression severity.
Time frame: 12 weeks after second psilocybin administration
Hamilton Anxiety Scale
The Hamilton Anxiety Scale is a 14-item clinician-administered tool used to quantify the severity of anxiety symptoms. Each item is scored from 0 (not present) to 4 (very severe), with a total score range of a minimum score of 0 and a maximum score of 56. Higher scores indicate higher anxiety symptoms.
Time frame: 12 weeks after second psilocybin administration
Sheehan Disability Scale
The Sheehan Disability Scale is a 3-item self-reported tool measuring functional impairment in work, social life, and family life, each rated from 0 (not at all) to 10 (extremely). Total scores range from a minimum score of 0 and a maximum score of 30; higher scores indicate greater impairment.
Time frame: 12 weeks after second psilocybin administration
World Health Organization 5-Wellbeing Index
The World Health Organization 5-Wellbeing Index is a 5-item, self-reported questionnaire assessing subjective psychological well-being over the past two weeks. Respondents rate items from 0 ("at no time"), with total raw scores (0-25) multiplied by 4, to generate a final 0-100 score. A maximum score of 100 indicates the best well-being, while a minimum score of 0 indicates the worst.
Time frame: 12 weeks after second psilocybin administration
Plan to share: No — no plans to share IPD
Started May 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.
Of 47 non-industry phase 1 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 59. This study's planned 12 months is below that.
Counting every sponsor, half of 52 studies reached it within 33 months; a quarter within 17 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Psilocybin
Stress Disorders, Post-Traumatic →